AroCell Overview
- Founded
- 2003
- Status
- Public
- Employees
- 12
- Stock Symbol
- AROC
- Investments
- 1
- Share Price
- $0.04
- (As of Friday Closing)
AroCell General Information
Description
AroCell AB is working in the area of cancer diagnostics. The company develops and commercializes markers for the determination of cell growth and apoptosis, clinically useful for prognosis, monitoring, and follow-up of cancer patients in Sweden.
Contact Information
Website
www.arocell.com
Formerly Known As
Xi Bao Research
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
STO
Primary Office
- Uppsala Business Park
- Virdings allé 32 B
- 754 50 Uppsala
- Sweden
+46 018-50 00 00
AroCell Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.04 | $0.04 | $0.04 - $0.76 | $10.2M | 230M | 588K | -$0.06 |
AroCell Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 10,518 | 9,352 | 16,487 | 3,209 |
| Revenue | 2,235 | 1,397 | 9 | 47 |
| EBITDA | (6,820) | (5,331) | (2,110) | (1,713) |
| Net Income | (6,734) | (5,825) | (2,609) | (2,192) |
| Total Assets | 31,845 | 25,129 | 7,372 | 9,773 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AroCell Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore AroCell‘s full profile, request access.
Request a free trialAroCell Patents
AroCell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6715770-B2 | Monoclonal anti-tk1 antibody | Active | 19-Dec-2013 | 000000000 | |
| US-20160311927-A1 | Monoclonal anti-tk1 antibodies | Granted | 19-Dec-2013 | 000000000 | |
| US-10100128-B2 | Monoclonal anti-tk1 antibodies | Active | 19-Dec-2013 | 000000000 | 0 |
| ES-2737626-T3 | Monoclonal anti-tk1 antibodies | Active | 19-Dec-2013 | 000000000 | |
| EP-3083698-B1 | Monoclonal anti-tk1 antibodies | Active | 19-Dec-2013 | C07K16/40 |
AroCell Executive Team (14)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Anders Hultman | Chief Executive Officer | ||
| Alona Nyberg | Marketing Director | ||
| Bernhard Tribukait | Co-Founder | ||
| Qi Min He | Co-Founder | ||
| Sven Skog | Co-Founder |
AroCell Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Claes Post | AroCell | Chairman | 000 0000 |
| Staffan Eriksson Ph.D | Self | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
AroCell Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAroCell Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore AroCell‘s full profile, request access.
Request a free trialAroCell Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 0000000 | 01-Jul-2021 | 0000000000 | Diagnostic Equipment | 00000 000 |